USPTO Patent Grants - Peptides (C07K)

Monoclonal antibody matrix metalloproteinase-1 patent granted

USPTO granted Patent US12595315B2 to S&T BIOMED CO., LTD. for a monoclonal antibody specific to matrix metalloproteinase-1. The patent covers the antibody's heavy and light chain variable regions with specific CDR sequences, along with polynucleotides, detection kits, and detection methods. This grant date is April 7, 2026.

TfR1 Humanized Antibodies and Cancer Treatment Methods

The USPTO issued Patent US12595310B2 to The Regents of the University of California covering transferrin receptor 1 (TfR1)-binding proteins, including humanized antibodies and methods for treating cancer. The patent, granted on April 7, 2026, includes 20 claims and was filed on November 6, 2020 under Application No. 17775167. The invention relates to humanized TfR1-binding proteins with amino acid substitutions, combination treatments with additional therapeutics, and methods for cancer therapy.

GPC3 antibody patent - methods of use for cancer treatment

The USPTO granted patent US12595314B2 to R.P. Scherer Technologies, LLC for antibodies specific to glypican-3 (GPC3). The patent covers 37 claims including the antibody compositions, nucleic acids encoding the antibodies, methods of manufacturing, and therapeutic uses for treating cell proliferative disorders by enhancing immune responses such as T cell responses to cancer cells.

Analyte Detection Immunoassay Patent Grant

USPTO granted Promega Corporation patent US12596119B2 covering compositions, kits, and methods for performing analyte detection immunoassays. The patent contains 11 claims and lists inventors Nidhi Nath, Rod Flemming, and Marjeta Urh. The patent application was filed on April 26, 2022.

Means and methods for detecting soy allergens

The USPTO granted Patent US12596111B2 to Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. covering methods for manufacturing antibodies that specifically bind to soy Gly m 8 protein and methods for detecting soy material in food or feedstuff preparations using said antibodies. The patent includes 12 claims and covers antibody production via plant-based protein expression, particularly in tobacco plants.

IGF-1R Antibody Compositions for Treatment of Thyroid Eye Disease

The USPTO granted Patent US12595309B2 to Viridian Therapeutics, Inc. covering insulin-like growth factor-1 receptor (IGF-1R) antibody compositions and methods for treating thyroid eye disease (TED). The patent includes 23 claims directed to pharmaceutical compositions and methods of reducing proptosis and Clinical Activity Score (CAS) by inhibiting IGF-1R activity. The patent claims priority to Application No. 18942051, filed November 8, 2024.

TREM2 stabilizing antibodies, Novartis AG, patent grant

The USPTO granted Patent US12595305B2 to Novartis AG on April 7, 2026, covering antibodies that bind to and stabilize human TREM2 protein. The patent names nine inventors and includes 10 claims, establishing Novartis's exclusive rights to this antibody technology.

CLDN18.2 binding molecule patent granted to Sanyou

CLDN18.2 binding molecule patent granted to Sanyou

CD8-specific capture agents, compositions, and methods of using and making

The USPTO granted Regeneron Pharmaceuticals patent US12594350B2 covering stable peptide-based CD8 capture agents for use as detection agents. The patent was issued April 7, 2026, naming Regeneron Pharmaceuticals, Inc. as assignee and Heather Dawn Agnew and Bert Tsunyin Lai as inventors. The application, filed April 4, 2017 (Application No. 15478596), contains 13 claims.

Virus-like Particles Patent Granted to University of Denver

The USPTO granted Patent US12594329B2 to the University of Denver on April 7, 2026. The patent covers virus-like particles, compositions, antibody detection tests using virus-like particles, and methods of producing non-replicating virus-like particles from modified viral genomes. Schuyler B. van Engelenburg is the sole inventor of the 9-claim patent.

Temperature-Optimized Bacillus Strains Patent Grant

The USPTO granted patent US12593849B2 to Chr. Hansen A/S on April 7, 2026, covering new strains of Bacillus paralicheniformis with improved growth rates and plant growth promoting properties. The patent names six inventors including Patricia Dominguez Cuevas and Lars Moelbak, with 21 claims. Filing date was August 28, 2020, under application number 17638152.

Bispecific CAR Targeting CD19 and CD20 for Cancer Treatment

USPTO granted Patent US12594321B2 to Novartis AG for a bispecific chimeric antigen receptor (CAR) targeting CD19 and CD20 for cancer treatment. The patent covers CAR proteins, encoding nucleic acids, vectors, and methods for treating diseases associated with CD20 or CD22 expression using modified T or NK cells. The patent includes 18 claims and lists 6 inventors.

Single domain antibodies for cancer therapy, Institut Curie

USPTO granted Patent US12594302B2 to Institut Curie covering fully humanized anti-FGFR4 single domain antibodies (sdAbs), functionalized drug nanocarriers, and compositions for cancer therapy. The patent includes 24 claims and covers nucleic acids, vectors, host cells, and immune cells comprising said sdAbs. The invention relates to FGFR4-targeted therapies for treating cancer.

Quorum Sensing Compositions and Methods for Microbial Community Modulation

USPTO granted patent US12594307B2 to The Regents of the University of California for quorum sensing compositions and methods for modulating bacterial quorum sensing. The patent covers engineered bacterial strains with multiple activator polypeptide-encoding sequences and methods for tunable dynamics in microbial communities. Inventors include Jeff Hasty, Arianna Miano, and Michael Julius Liao, with applications spanning synthetic biology and therapeutic development.

Combination therapies against cancer targeting CD38 and TGF-β

USPTO granted Sanofi Patent US12590167B2 covering combination cancer therapies targeting CD38 and TGF-β using specific antibodies. The patent (11 claims) was granted March 31, 2026, with a filing date of July 10, 2019. This patent relates to compositions and methods for treating cancer using dual-antibody therapy.

Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof

USPTO granted Regeneron Pharmaceuticals Patent No. US12590168B2 covering CD38/CD28 bispecific antibodies designed to activate T-cells and inhibit tumor growth. The patent includes 35 claims and covers methods for treating cancers including multiple myeloma, lymphoma, and leukemia using bispecific antigen-binding molecules.

CD30+ Cancer Detection and Treatment Methods Patent

USPTO granted Patent US12590968B2 to Seagen Inc. for methods of diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers. The patent (Kind B2), with inventors Tina Albertson and Maria L. Smith, contains 4 claims covering CPC classifications A61K 47/6849, C07K 16/2878, and A61P 35/00. Application No. 17747591 was filed May 18, 2022.

Anti-C-MPL antibody and use thereof

USPTO granted patent US12590161B2 to Daegu Gyeongbuk Institute of Science and Technology for an anti-C-MPL antibody (2R13) that increases platelet production through megakaryocyte maturation. The antibody offers longer half-life than conventional therapeutic agents with lower self-antibody production and reduced immunogenicity. The patent covers therapeutic applications for chronic or complication-induced immune thrombocytopenia.

EGFR Bispecific Antibody Patent Grant - Amunix Pharmaceuticals

The USPTO granted patent US12590159B2 to Amunix Pharmaceuticals covering compositions targeting EGFR, including protease-activatable bispecific fusion proteins such as T cell engagers. The patent includes 8 claims for antibody binding domains targeting CD3 and EGFR, cleavable linker sequences, and methods of treatment for conditions such as cancer.

PD-L1 Binding Molecules and Uses Thereof

USPTO granted Patent US12590155B2 to Beijing Mabworks Biotech Co., Ltd. for molecules (single-domain antibodies and heavy chain only antibodies) that specifically bind human PD-L1 for use in treating tumors and related diseases. The patent contains 17 claims and covers the分子的 therapeutic applications in cancer treatment.

CD3-specific binding molecules

The USPTO granted Immunocore Limited Patent US12590152B2 covering CD3-specific binding molecules, specifically antibodies and fragments with improved properties. The patent contains 19 claims and names 8 inventors including Martina Canestraro and Stephen Harper. This is a routine patent grant establishing intellectual property rights without regulatory compliance obligations.

Bi-specific Chimeric Antigen Receptor for TGF-beta Binding

USPTO granted patent US12590145B2 to The Regents of the University of California on March 31, 2026, covering a bi-specific chimeric antigen receptor (CAR) that specifically binds TGF-beta. The CAR technology neutralizes TGF-beta while simultaneously triggering T-cell activation, converting an immunosuppressive signal into an activating stimulus. The patent contains 10 claims with application number 17323568, filed May 18, 2021.

Antibodies binding to citrullinated histone 2A and/or 4

USPTO granted Patent No. 12,590,143 B2 to Citryll B.V. for antibodies binding to citrullinated histone 2A and/or 4, covering therapeutic applications for Neutrophil Extracellular Trap (NET)-associated pathologies. The patent includes 13 claims and covers both the antibodies and binding fragments for use in treatment.

Anti-Henipavirus Monoclonal Antibodies with Broad Spectrum Neutralization

The USPTO granted Patent US12590141B2 to the Academy of Military Medical Science covering monoclonal antibodies targeting Henipavirus glycoprotein G. The patent claims antibodies combining macaque variable regions with human constant regions, demonstrating broad neutralization activity against Nipah and Hendra viruses. The patent includes 9 claims and covers encoding nucleic acids for therapeutic applications.

GLP-1 agonist polypeptide compound and salt thereof, synthesis method therefor and use thereof

USPTO granted patent US12590134B2 to SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD. for a GLP-1 agonist polypeptide compound (SEQ ID NO: 1) used in diabetes and obesity treatment. The patent includes 2 claims covering the compound, salt forms, synthesis method, and therapeutic applications. Filing date was August 17, 2022, under application number 17820251.

Bipartite molecules treating neurodegenerative diseases

USPTO granted Patent US12590130B2 to Academia Sinica for bipartite molecules comprising a peptide affinity moiety and charged moieties for treating neurodegenerative diseases associated with abnormal protein aggregates. The patent contains 6 claims and was granted March 31, 2026, with original filing date November 27, 2020. No compliance deadlines are associated with this patent grant.

Acetohydroxy acid synthase variant and microorganism including the same

USPTO granted patent US12590128B2 to CJ CheilJedang Corporation on March 31, 2026, for an acetohydroxy acid synthase variant, polynucleotides encoding it, microorganisms containing it, and a method for producing L-isoleucine using the microorganism. The patent has 20 claims.

Split PYP Complementation System for Detecting Protein Interactions

USPTO granted patent US12590127B2 to PARIS SCIENCES ET LETTRES for a split photoactive yellow protein (PYP) complementation system for detecting protein interactions. The patent covers two PYP fragments with at least 70% sequence identity to SEQ ID NO:23 and SEQ ID NO:34, used with fluorogenic HBR analogs for protein interaction detection. The grant includes 19 allowed claims.

Peptide with Neutralizing Activity Against SARS-CoV-2

The USPTO granted patent US12590124B2 to CAREGEN CO, LTD. for a peptide composition that specifically recognizes and neutralizes SARS-CoV-2. The patent covers both therapeutic applications for preventing or treating COVID-19 infection and diagnostic applications for detecting the virus. The patent contains 13 claims and lists 6 inventors.

Protease Inhibitor Compounds for Treating Cancer, Viral Infections, and Allergic Conditions

USPTO granted patent US12590123B2 to Washington University covering protease inhibitor compounds useful for treating coronaviruses, cancer, and allergic conditions. The patent discloses compounds inhibiting S1 serine proteases (HGFA, matriptase, hepsin, KLK5, TMPRSS2) and cysteine proteases with 10 claims. Filing date was June 25, 2020, with application number 17620169.

NRP-1 binding inhibitory peptides and uses thereof

USPTO granted patent US12590122B2 to INSERM for NRP-1 binding inhibitory peptides with anti-angiogenic properties for cancer treatment. The patent covers novel peptide-like compounds with nanomolar affinity for NRP-1 that inhibit VEGF-A165/NRP-1 interaction, representing an improvement over the prior A7R heptapeptide. Application 17618233 (filed June 10, 2020) contains 15 claims.

Materials and Methods for Isolating Self-Antigen Polypeptides

The USPTO issued Patent Grant US12590120B2 to Impact Proteomics covering materials and methods for isolating self-antigen polypeptides. The patent names inventors Jonathan Minden and Dana Ascherman and contains 19 claims. This grant confers exclusive rights to the patented technology for the patent term.

UFABC patents KLK7 antibodies, skin desquamation, 31st Mar

UFABC patents KLK7 antibodies, skin desquamation, 31st Mar

Peptide-derived KDM5C targeting cancer therapeutics patent grant

USPTO granted Patent US12589160B2 to NUVOBIO CORPORATION covering peptide-derived therapeutics targeting KDM5C for cancer treatment. The patent, filed on March 12, 2020, contains 6 claims and names inventors Kyle Kevin Biggar, Hemanta Adhikary, and Matthew Jacob Hoekstra. This grant establishes exclusive intellectual property rights for the assignee in the United States.

Multivalent HVT vector vaccine for poultry

USPTO granted Patent US12589147B2 to Intervet Inc. for a recombinant herpesvirus of turkeys (rHVT) vector vaccine expressing antigens from IBDV, NDV, and AIV. The patent covers 20 claims and can be used to vaccinate poultry against four diseases: MDV, IBDV, NDV, and AIV simultaneously.

HLA tumor antigen peptides of class I and II for treating mammary/breast carcinomas

The USPTO granted Patent US12589142B2 to PMCR GmbH covering pharmaceutical compositions comprising HLA-A tumor antigen peptides (4-8 peptides for MHC class I and 2+ for MHC class II) for treating breast carcinomas. The patent includes 4 claims and covers methods for preparing the composition and determining HLA peptides.

Production of antibodies by modification of autonomous heavy chain variable domain via gene conversion

USPTO granted patent US12588664B2 to Crystal Bioscience Inc. on March 31, 2026. The patent covers transgenic animals engineered with B cells that use gene conversion for antibody diversification, involving functional immunoglobulin heavy chain genes and operably linked pseudogenes that donate sequence to enable diversification.

Cerebrolysin patent for CADASIL treatment

USPTO granted patent US12589118B2 to Ever Neuro Pharma GmbH for a method of using cerebrolysin to reduce mortality in patients with CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). The patent includes 15 claims and was filed on August 28, 2018.

Method for producing modified pea protein

USPTO granted patent US12588686B2 to Ajinomoto Co., Inc. covering methods for producing modified pea protein with improved solubility. The method involves treating pea ground product with acid and conducting enzyme reactions using protein deamidase. The patent contains 4 claims and names three inventors.

177Lu peptide targets uPAR receptor for colorectal cancer treatment

USPTO granted patent US12589171B2 to TRT INNOVATIONS APS covering a 177-Lu labeled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) for treatment of cancers with high uPAR expression, particularly colorectal cancer. The patent includes 9 claims and lists inventors Andreas Kjaer, Morten Persson, and Michael Ploug.

CD80 Extracellular Domain Fc Fusion Proteins for Treating PD-L1 Negative Tumors

The USPTO granted Patent US12589132B2 to Five Prime Therapeutics, Inc. covering fusion proteins combining the CD80 extracellular domain with the Fc domain of IgG1 for treating PD-L1 negative tumors. The patent includes 22 claims and names Susannah D. Barbee, Thomas Brennan, and Barbara Sennino as inventors. This grant establishes exclusive rights for the assignee in this therapeutic application.

Root-knot Nematode Resistance Gene Patent Grant

USPTO granted patent US12588644B2 to Rijk Zwaan Zaadteelt En Zaadhandel B.V. covering a nucleic acid encoding the MeR1 protein that confers resistance to root-knot nematode in Solanaceae plants. The patent includes 18 claims covering the gene sequences, amino acid sequences, and methods of using the resistance gene in plant breeding. The inventors are Raoul Jacobus Johannes Maria Frijters, Jonathan Kalisvaart, and Adriaan Verhage.

Otoferlin Dual Vector Systems for Treating Sensorineural Hearing Loss

The USPTO granted Regeneron Pharmaceuticals Patent US12589168B2 for compositions and methods treating sensorineural hearing loss using otoferlin (OTOF) dual vector gene therapy systems. The patent covers a two-vector approach delivering N-terminal and C-terminal portions of OTOF isoform 5 to restore gene function in patients with OTOF mutations. Application No. 17733744 was filed April 29, 2022.

Patent Grant: IGFR-like Receptor Antagonists for Diabetes Treatment

The USPTO has granted a patent (US12583928B2) for novel Insulin-like Growth Factor 1 Receptor (IGFR)-like receptor antagonists and agonists. These compounds are intended for the treatment of diabetes.

USPTO Patent Granted for MUC1 Antibodies for Cancer Treatment

The USPTO has granted patent US12583927B2 to Minerva Biotechnologies Corporation for MUC1 antibodies designed for cancer treatment. The patent covers antibodies that specifically bind to the PSMGFR peptide or its fragments, offering potential new diagnostic and therapeutic applications.

USPTO Patent Grant: Bispecific Antibodies Targeting CD47 and PD-L1

The USPTO has granted patent US12583922B2 for bispecific antibodies targeting CD47 and PD-L1. The patent, assigned to Novimmune SA, covers methods of making and using these antibodies for treating cancers associated with malignant cells expressing CD47 and/or PD-L1.

USPTO Patent Grant: Antibody and CAR Binding to CD70 for Disease Treatment

The USPTO has granted patent US12583931B2 to Nanjing IASO Biotechnology Co., Ltd. for an antibody and chimeric antigen receptor (CAR) that specifically binds to CD70, intended for treating diseases related to CD70 expression. The patent covers the composition of the CAR and its application in disease treatment.

USPTO Patent Grant US12583892B2: Conus Peptides for Neurodegenerative Conditions

The USPTO has granted patent US12583892B2 to Technion Research and Development Foundation Limited for modified Conantokin peptides and their use in treating neurodegenerative conditions. The patent covers specific peptide forms, nucleic acids encoding them, and compositions for modulating NMDA receptors.

USPTO Patent Grant for Peptides Treating Type 1 Diabetes

The USPTO has granted patent US12583891B2 to PHOENIX ALPHA for peptides and methods used in the treatment of type 1 diabetes. The patent covers specific peptide sequences and their application in generating cytolytic CD4+ T cells.

Bi-specific Peptides for Cancer Treatment Granted Patent

The USPTO has granted a patent (US12583888B2) to the University of Tartu for bi-specific peptides designed to target cancer cells and the extracellular matrix. These peptides bind to fibronectin extra domain B (FN-EDB) and/or tenascin-C C domain (TNC-C). The patent was granted on March 24, 2026.